Moment is not right for VU's drug patent bid

Home

Moment is not right for VU's drug patent bid

Written by Administrator

Wednesday, 28 April 2010 20:21

Vanderbilt University has tried harder in recent years to prove he deserves a stake of more than 6 billion in sales resulting from the erectile dysfunction drug Cialis since 2002.

But put the patent owner Cialis fierce resistance, and last week a federal appeals court Vanderbilt allowed to continue.

However, few had high hopes again. University and the lawyers and decide now whether to appeal to the Supreme Court of the United States.

In July 2005, the company filed a lawsuit against Vanderbilt flags, and now a unit of pharmaceutical giant Eli Lilly & Co., in the district court in Delaware in the United States. The case and claimed that members of the faculty of Vanderbilt Jackie Corbin, Sharron Konjeti Francis Raja should share the right to patent Coe, the active ingredient in Cialis. Corbin and Francis, and professors of physiology and molecular physics, and Konjeti is a professor of radiation oncology.

The University provided evidence that the scientists were working on "inhibitors PDE5", a category of enzymes that includes ku, in the late 1980s when it entered into a research collaboration with Pharma Glaxo information provided and to study inhibitor for PDE5 researcher Glaxo UK for several years. Developing world, Glaxo France, Marie-Claude Alan Daugan, Co between 1992 and 1994 - based largely on the work done by Corbin, Francis and Konjeti, according to the lawsuit.

Daugan are listed on the patent and the sole inventor of a sharp drop. Flags later got the rights to the patent.

Has been detected at very successful financial patent holders. Increased sales of Cialis to 1.6 billion dollars in 2009, according to the following filings made by the Commission with the Securities and Exchange Commission. The company said more than 6.5 billion dollars of proceeds from the drug since its introduction in 2002. Is still under patent protection until 2017.

But David Williams II, The Vanderbilt Vice Chancellor for University Affairs and General Counsel, this week that legal action did not seek a specific amount in damages.

"Certainly there are dollars in all of this, but what we were trying to say is that these people contributed greatly to the development of this compound, and thus should have been contained as inventors," said Williams, NashvillePost.com. "He added that this does not mean that from the beginning, he should participate in the" proceeds from the sale of medicine.

The legal victory of the University means that members of the WVU faculty itself will get all proceeds from sales of Cialis, but Williams said he was "almost impossible to say" how much money may be at stake.

Now, however, the only way can prevail Fu will be the Supreme Court to choose this issue as one of the few he can hear each term, many seek to go before the judges, and then to make a decision in favor of Vanderbilt.

At the provincial level, and the few able to convince a judge that the French researcher has knowingly made use of information that belong to Corbin, Francis and Konjeti. On appeal, a panel of three judges in the Federal Circuit found that the court had "applied the wrong standard joint inventor," but two of the three scholars found that the decision in favor of ICOS was true anyway. (This provision is available on this link).

A third judge, which was published in the opposition, saying that it should be lower-court decision overturned because of an error.

Williams said he will collect contributions from lawyers and staff lawyers and outside the office of the university in technology transfer and development projects on whether to pursue an appeal to the Supreme Court. It will also explore whether any of the entities that have an interest in issues of patent law to play in this issue and support the position of Fu through a friend of the court briefs.

"Based on that feedback, we will sit down with the Chancellor and others in the administration to take a decision on what we are going to do after that," said Williams.

Main Menu

Categories